![DNAtrix](https://gocience.com/logos/new/2cdfd45199e2cb264ccc41c4fddfc0697529266b7bbbd8297bf318a8322396b3.jpg)
Dn Atrix
Biotechnology, 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States, 11-50 Employees
Phone Number: 83********
Who is DNATRIX
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common co...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States
-
Date Founded: 2005
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 3829
|
NAICS Code: 339112 |
Show More
DNAtrix Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding DNAtrix
Answer: DNAtrix's headquarters are located at 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States
Answer: DNAtrix's phone number is 83********
Answer: DNAtrix's official website is https://dnatrix.com
Answer: DNAtrix's revenue is $10 Million to $25 Million
Answer: DNAtrix's SIC: 3829
Answer: DNAtrix's NAICS: 339112
Answer: DNAtrix has 11-50 employees
Answer: DNAtrix is in Biotechnology
Answer: DNAtrix contact info: Phone number: 83******** Website: https://dnatrix.com
Answer: DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The companys lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The companys investors include Morningside Ventures and Mercury Fund.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month